• Home
  •  / Sensei Biotherapeutics

Sensei Biotherapeutics

  • Market Capitalization$61 M2022-08-04

OverviewSuggest Edit

Sensei Biotherapeutics (formerly known as Panacea Pharmaceuticals) is a biotechnology company developing biologics therapies targeting key components of the immune system for the treatment of cancers. It offers a pipeline of immune-activating agents for an array of cancers including solid tumors and hematological malignancies.
TypePublic
Founded1999
HQRockville, MD, USMap
Websitesenseibio.com
Overall CultureA-More
View Jobs (3)

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2020)25
Job Openings3
Share Price (Aug 2022)$2
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sensei Biotherapeutics

John K. Celebi

John K. Celebi

President and CEO, Director
Robert Pierce

Robert Pierce

Chief Scientific Officer
Erin Colgan

Erin Colgan

Senior Vice President, Finance
Alice Drumheller

Alice Drumheller

Vice President, Clinical Operations
Michael Boychyn

Michael Boychyn

Senior Vice President of CMC
Pauline Callinan

Pauline Callinan

Vice President, Business Operations and Strategy
Show more

Sensei Biotherapeutics Office Locations

Sensei Biotherapeutics has offices in Rockville and Boston
Rockville, MD, US (HQ)
1405 Research Blvd #125
Boston, MA, US
6 Tide St
Show all (2)

Sensei Biotherapeutics Financials and Metrics

Sensei Biotherapeutics Revenue

USD

Net income (Q1, 2022)

(12.4m)

EBIT (Q1, 2022)

(12.5m)

Market capitalization (4-Aug-2022)

61.0m

Closing stock price (4-Aug-2022)

2.0
Sensei Biotherapeutics's current market capitalization is $61 m.
Annual
USDFY, 2018FY, 2019FY, 2021

General and administrative expense

4.5m4.1m15.8m

R&D expense

8.2m8.4m

Operating expense total

12.7m12.4m

EBIT

(12.7m)(12.4m)(37.5m)
Quarterly
USDQ1, 2021Q2, 2021Q3, 2021Q1, 2022

General and administrative expense

4.6m3.9m3.9m5.0m

R&D expense

3.4m

Operating expense total

8.0m

EBIT

(8.0m)(9.8m)(10.3m)(12.5m)
show all
Annual
USDFY, 2018FY, 2019FY, 2021

Cash

653.0k251.0k

Prepaid Expenses

504.0k251.0k

Current Assets

1.3m502.0k

PP&E

123.0k268.0k
Quarterly
USDQ3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

3.7m169.4m15.6m9.5m

Prepaid Expenses

696.0k3.3m2.6m1.2m

Current Assets

4.4m172.8m165.6m158.2m

PP&E

1.1m1.7m2.1m3.1m
show all
Annual
USDFY, 2018FY, 2019FY, 2021

Net Income

(13.0m)(16.7m)(36.8m)

Depreciation and Amortization

44.0k73.0k685.0k

Accounts Payable

931.0k2.3m(1.4m)

Cash From Operating Activities

(10.3m)(8.6m)(30.3m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(10.0m)(15.0m)(8.0m)(17.7m)(27.4m)(12.4m)

Depreciation and Amortization

50.0k139.0k98.0k220.0k356.0k157.0k

Accounts Payable

718.0k(2.5m)(1.9m)(1.1m)(408.0k)2.6m

Cash From Operating Activities

(6.9m)(15.0m)(10.8m)(16.8m)(22.4m)(10.7m)
show all
USDFY, 2018

Debt/Equity

-0.1 x

Debt/Assets

2.6 x
Show all financial metrics

Sensei Biotherapeutics Operating Metrics

Dec, 2020

Patent Applications (Foreign)

9

Patent Applications (US)

5

Patents (Foreign)

2

Patents (US)

4

Sensei Biotherapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Alvaxa Biosciences, Inc.May 18, 2020
Panacea Pharmaceuticals, Inc.

Sensei Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

Sensei Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

Sensei Biotherapeutics Online and Social Media Presence

Sensei Biotherapeutics's Trends

Embed Graph

Sensei Biotherapeutics Company Culture

  • Overall Culture

    A-

    88/100

  • CEO Rating

    A+

    94/100

  • Compensation

    A+

    93/100

  • Diversity

    B+

    87/100

Learn more on Comparably

Sensei Biotherapeutics News and Updates

May 10, 2022

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors -
March 10, 2022

Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA -
March 09, 2022

Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors

Brings decades of both board and management life sciences experience Brings decades of both board and management life sciences experience
March 03, 2022

Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in the 32nd Annual Oppenheimer Healthcare C…
February 11, 2022

Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in Citi's 2022 Immuno-Oncology Summit.
January 06, 2022

Sensei Biotherapeutics Announces Executive Promotions

Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer
Show more

 Sensei Biotherapeutics Frequently Asked Questions

  • When was Sensei Biotherapeutics founded?

    Sensei Biotherapeutics was founded in 1999.

  • Who are Sensei Biotherapeutics key executives?

    Sensei Biotherapeutics's key executives are John K. Celebi, Robert Pierce and Erin Colgan.

  • How many employees does Sensei Biotherapeutics have?

    Sensei Biotherapeutics has 25 employees.

  • Who are Sensei Biotherapeutics competitors?

    Competitors of Sensei Biotherapeutics include NovoCure, Neovii and Eutilex.

  • Where is Sensei Biotherapeutics headquarters?

    Sensei Biotherapeutics headquarters is located at 1405 Research Blvd #125, Rockville.

  • Where are Sensei Biotherapeutics offices?

    Sensei Biotherapeutics has offices in Rockville and Boston.

  • How many offices does Sensei Biotherapeutics have?

    Sensei Biotherapeutics has 2 offices.